Johnson and Johnson (France) Company Profile

17:45 EDT 2nd September 2015 | BioPortfolio

Our pharmaceuticals companies offer medicines that treat many of the world's most serious and widespread diseases. These diseases range from cancer, HIV/AIDS and bacterial infections to schizophrenia, epilepsy, rheumatoid arthritis and psoriasis. In 2007, we invested $5.3 billion in the search for new ways to treat these diseases and many others. It’s all part of our commitment to helping you and the ones you love lead longer, healthier lives.

These companies are organized into three global business units:

Central Nervous System and Internal Medicine

This business unit develops medicines for an array of health problems, including central nervous system disorders, such as schizophrenia and epilepsy; metabolic diseases, such as diabetes; cardiovascular diseases; and infectious diseases.

B.I.O. (Biotechnology, Immunology & Oncology)

This business unit develops traditional and biologic medicines to treat autoimmune disorders, such as rheumatoid arthritis, psoriasis, and Crohn’s disease; a wide range of cancers; and blood disorders, such as anemia.

Virology

This business unit develops medicines for the treatment of infectious diseases, such as HIV/AIDS, hepatitis C and tuberculosis.

Location

rue camille desmoulins
issy les moulineaux cedex 9
F-92787
France

Contact

Phone: 33-155004174


News Articles [1305 Associated News Articles listed on BioPortfolio]

Johnson & Johnson Innovation inks 17 collaborations

Johnson & Johnson Innovation has announced 17 new collaborations with research institutions and healthcare companies, bringing the total number of collaborations formed since the 2013 launch of Johns...

Johnson & Johnson posts 2Q profit, results beat Street expectations

Johnson & Johnson (JNJ) on Tuesday reported second-quarter net income of $4.52 billion.

Johnson & Johnson 1st-qtr beats expectations despite profits decline

US health care giant Johnson & Johnson was first out of the blocks in reporting first-quarter 2015 financial…

Johnson and Johnson CEO: Cancer Research Is Paying Off

Johnson and Johnson has 10 new products in the pharmaceutical pipeline that could potentially earn the company $10 billion in revenue, according to CEO Alec Gorsky.

Johnson & Johnson tops 1Q net income and revenue expectations

Johnson & Johnson (JNJ) on Tuesday reported first-quarter profit of $4.32 billion.

Johnson & Johnson to challenge Novartis in axial spondyloarthrtis treatment space; report

US health care giant Johnson & Johnson’s psoriasis drug, Stelara (ustekinumab), has progressed into…

LDC to Collaborate with Johnson & Johnson Innovation on Acceleration of Academic Drug Discovery Initiatives

The Lead Discovery Center GmbH (LDC) and Johnson & Johnson Innovation Ltd., will collaborate to identify and accelerate drug candidates for the treatment and prevention of diseases with high unmet med...

Johnson & Johnson Boosts Dividend 7.1%

NEW BRUNSWICK (dpa-AFX) - Healthcare products maker Johnson & Johnson (JNJ) said Thursday that its Board of Directors has declared a 7.1% increase in the quarterly dividend rate, from $0.70 per sh...

PubMed Articles [319 Associated PubMed Articles listed on BioPortfolio]

Danazol-induced Stevens-Johnson syndrome in a patient with systemic lupus erythematosus.

A patient with Stevens-Johnson syndrome related to danazol is presented.

Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women.

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) form a spectrum of a rare and life-threatening cutaneous drug reaction. SJS/TEN in pregnancy poses largely unknown risk factors and ...

Stevens-Johnson Syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People's Republic of China.

Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but severe cutaneous drug reactions. They are differentiated based on the fraction of the body surface area affected. Optim...

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Ear, Nose, and Throat Description at Acute Stage and After Remission.

Ear, nose, and throat (ENT) lesions are frequently involved in Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), although a detailed description is lacking in the literature.

Predictive Factors associated with Acute Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

To suggest an objective score for grading the acute ocular severity of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), and to determine predictive factors for severe acute ocular ...

Clinical Trials [203 Associated Clinical Trials listed on BioPortfolio]

Stevens-Johnson Syndrome Antimicrobial

Steven-Johnson's syndrome, or great multiform erythema, appears as a systemic disturbance, with skin involvement and mucous membranes, related to several factors, such as, viral or bacteri...

Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion crit...

Extracorporeal Photopheresis Pilot Study

ECP will be given to the patients [UVAR®XTS TM Therakos system, Johnson & Johnson] according to the following schedule: Starting at day 21 after transplant, if hematologic recovery allow...

A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition

The study was conducted as an open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioavailability study comparing famotidine tablets, USP 20 ...

A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition

The study was conducted as an open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioavailability study comparing famotidine tablets, USP 20 ...

Companies [453 Associated Companies listed on BioPortfolio]

Johnson and Johnson

Johnson & Johnson, employing approximately 119,000 people worldwide, is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. Johnso...

Johnson & Johnson Innovation

The London Innovation Centre is part of Johnson & Johnson Innovation, a division of Johnson & Johnson Finance Limited. Johnson & Johnson Innovation focuses on accelerating early i...

Johnson & Johnson (China) Investment Co., Ltd.

Johnson & Johnson (China) Investment Co., Ltd. is a foreign investment entity established in China by Johnson & Johnson in 1998. For more information about Johnson & Johnson and its operating unit...

JOHNSON'S(R) Brand

JOHNSON'S® Brand from Johnson & Johnson Consumer Products Company, Division of Johnson & Johnson Consumer Companies, Inc., has a long tradition of providing pure, mild, gentle and clinically-proven p...

JANSSEN-ORTHO INC

Since 1961 Janssen-Cilag has been a member of the Johnson & Johnson family of companies. Founded in 1886, Johnson & Johnson today is the world's most comprehensive manufacturer of healthcare products ...

More Information about "Johnson and Johnson (France)" on BioPortfolio

We have published hundreds of Johnson and Johnson (France) news stories on BioPortfolio along with dozens of Johnson and Johnson (France) Clinical Trials and PubMed Articles about Johnson and Johnson (France) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Johnson and Johnson (France) Companies in our database. You can also find out about relevant Johnson and Johnson (France) Drugs and Medications on this site too.


Advertisement
 

Relevant Topics

Cancer
Latest News Clinical Trials Research Drugs Reports Corporate
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Psychiatry
Latest News Clinical Trials Research Drugs Reports Corporate
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record